Cancer Guidelines Name Adaptive's clonoSEQ Testing

The National Comprehensive Cancer Network's updated multiple myeloma guidelines now name Adaptive Biotechnologies' clonoSEQ assay and expand the recommended testing time points to include annual assessments during maintenance therapy and testing after later lines of treatment, according to the company's September 17 announcement.

For Adaptive (NASDAQ:ADPT), the stakes are straightforward: more recommended testing moments could mean more orders per patient over the course of treatment. The guidelines strengthen the case for monitoring minimal residual disease, or MRD — the small amounts of cancer that remain after treatment. The preferred sensitivity threshold is one cancer cell in one million cells, with one in 100,000 set as the recommended minimum.

The Commercial Baseline

Adaptive enters this moment with existing momentum. Second-quarter clonoSEQ volume rose 43% year over year to 36,111 tests delivered. MRD business revenue climbed 33% to $66.2 million. In July, management raised full-year MRD revenue guidance to a range of $268 million to $278 million.

Those numbers predate the September guideline announcement. They serve as a baseline for judging whether broader recommendations convert into additional adoption in the quarters ahead.

The Bull Case

Annual maintenance testing could generate repeat orders from patients already using clonoSEQ. The new recommendations also cover later treatment lines, including CAR T-cell therapy, which creates openings for Adaptive to maintain testing relationships as a patient's care evolves.

If clinicians fold these assessments into routine workflows, revenue growth could benefit on two fronts: new patients entering the testing funnel and more tests per existing patient.

Reimbursement already has a foothold. Medicare covers clonoSEQ for multiple myeloma, giving Adaptive an established payment foundation. More explicit clinical recommendations could strengthen the company's discussions with both physicians and payers.

The Bear Case

The guidelines do not hand clonoSEQ a monopoly. They also permit multicolor flow cytometry. Being the only assay named in the recommendations gives clonoSEQ visibility, but it does not make it the exclusive testing option.

Adaptive still needs the recommendations to translate into completed, reimbursed tests. The guidance concerns bone-marrow-based assessments, which puts a premium on sample collection logistics and clinical scheduling for repeat testing. Physician judgment, patient circumstances, and payer rules will all shape actual utilization.

Existing Medicare coverage also does not guarantee payment for every recommended test under every insurance plan. Higher volume creates value only if realized reimbursement remains attractive and laboratory costs grow more slowly than revenue.

What to Watch

The September guideline update has already lifted clonoSEQ's clinical profile. Whether it lifts the top line depends on whether annual maintenance testing and later-line assessments become routine in practice — and whether Adaptive captures that volume at margins that hold up as test counts rise.